Global Report - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Global Report

Report From Brazil

March 2, 2011

Pharmaceutical Technology

Brazil develops its first national plasma fractionation plant.

Report from India

February 2, 2011

Pharmaceutical Technology

As biologic-drug patents move toward expiration in the US, Indian firms with experience in the follow-on biologics arena are eager to partner with global manufacturers and secure their place in the growing biosimilars market.

Report from Europe

January 2, 2011

Pharmaceutical Technology

The European Commission and Medicines Agency seem to be moving in advance of their ICH partners to update standards.

Report from Asia

December 2, 2010

Pharmaceutical Technology

Global pharmaceutical companies have much to gain in Asia, and the good news is that it's a two-way street. Firms based in Asia are also expected to grow at the global level.

Report from India

November 2, 2010

Pharmaceutical Technology

IP rights and levels of innovation have opened a bit of controversy regarding decisions being made by Indian courts and legislators.

Report from Europe

October 2, 2010

Pharmaceutical Technology

Public-private R&D partnerships are on the rise across Europe, but national goals and academia-industry competition could prevent their success at the European level.

Report from Brazil

September 2, 2010

Pharmaceutical Technology

A look at why Brazil revised its GMP standards and how the changes will affect the local pharmaceutical industry.

Report from Asia

August 2, 2010

Pharmaceutical Technology

Manufacturers and regulators on both sides of the ocean move to ensure the safety of heparin and other globally distributed drug products.

Report from India

July 2, 2010

Pharmaceutical Technology

As generic divisions become the most-wanted acquisitions of Big Pharma, India's domestic industry may be thinning out.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Click here